

ACTIVAERO AND UNIVERSITY OF GIESSEN RECEIVE GRANT AND ANNOUNCE COLLABORATION FOR THE DEVELOPMENT OF AKITA JET

Gemünden and Gießen, Germany, November 19, 2008 – Activaero GmbH, the world leader in controlled breathing technologies for inhaled therapeutic agents, and the University of Gießen Lung Center today announced a collaboration for the co-development of the next generation inhalation device AKITA JET. The joint project will be supported by a grant from HessenAgentur GmbH that totals up to € 170,000.

Compared to the currently available AKITA device, AKITA JET is smaller, more flexible, lighter and more affordable device for controlled and personalized inhalation therapy. The development of this device should make state-of-the-art inhalation therapy available to more patients.

The UGLC has a long standing record in the research of lung diseases and the development of new therapies. Under the terms of the collaboration, the UGLC will perform clinical studies to establish medical effectiveness. Activaero has already produced ten prototypes of the new AKITA JET system for testing purposes.

HessenAgentur promotes research and development institutions in the German state of Hessen and arranged the grant under the new LOEWE program for the development of economic and scientific excellence.

“Activaero is the established world leader in the development of controlled inhalation technologies,” Dr. Gerhard Scheuch, Founder and CEO of Activaero said “and this grant will enable us to further develop and expand the excellent relations to the researchers at the UGLC in Gießen.”

“We expect that the high efficiency of the AKITA System will result in a meaningful improvement in the medical treatment of patients with chronic lung diseases. As an example, we expect that use of the AKITA system may help to reduce the need for systemic steroid treatment in asthma patients,” added Prof. Andreas Günther of the University of Giessen Lung Center.

About Activaero:

Activaero is the world leader in controlled breathing technologies for inhaled therapeutic agents. With stand alone inhalation products and inhalation systems available for clinical trials and marketing partnerships, Activaero’s technologies allow for the most precise and efficient patient-tailored pulmonary delivery. Activaero currently has two products on the market, AKITA®, a patient-tailored controlled breathing system with a smartcard that records the patient dosing parameters, and Watchhaler™, a hand held delivery system tailored specifically to children. The Company also has available a range of technologies ideal for the controlled delivery of inhaled therapeutics in the clinical trial setting and tailored to specific partnerships (AKITA2®, LimiX™). Finally, Activaero works with partners on a consultancy basis in the development of ideal inhaled delivery systems and the logistics in clinical trials. Activaero’s technological approach has been

validated repeatedly in the clinical setting. The Company is privately held and located in Gemünden (Wohra) and Munich in Germany and Dublin, Ohio in the USA.

About UGLC

The UGLC is a collaborative research initiative at the Justus-Liebig-University Giessen, promoting translational lung research. Researchers and clinicians systematically transform cutting edge laboratory research into clinical applications for the benefit of patient health and medical care. The successful exchange of interdisciplinary expertise is stimulated by the proximity of laboratories, modern equipment, and patient care facilities. Additionally, clinical medicine and pulmonary research are complemented with a strong emphasis on education in respiratory medicine and molecular biology.

Further Information:

Axel Fischer
Managing Director
Activaero GmbH
Phone: +49 (0) 6453 64818-0
E-Mail: fischer@activaero.de

Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill
Phone: +49 (0)89 57 00 18 06
E-Mail: douglas.pretsell@collegehill.com

William C. Zimlich
Activaero America, Inc.
Phone: +1 (614) 761 3555
E-Mail: zimlich@activaero.com

 **LOEWE – Landes-Offensive zur
Entwicklung Wissenschaftlich-
ökonomischer Exzellenz**

Prof. Dr. Andreas Günther
University of Gießen Lung Center
Phone: +49 (641) 99 42502
E-Mail : andreas.guenther@uglc.de

Dieses Projekt (HA-Projekt-Nr.: 144/08-06) wird im Rahmen der Innovationsförderung des Landes Hessen gefördert, finanziert aus Mitteln der LOEWE - Landes-Offensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz, Förderlinie 3: KMU-Verbundvorhaben.